Optimi Health Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY Revenue (est.)
$478.1Knext fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue from Drug Product Sales Quarterly99.5K
Active Patient Treatments in Australia Monthly
Watch Items
- U.S. FDA Regulatory Approvals and Executive Orders on PsychedelicsTrigger: Accelerated FDA review or rescheduling of MDMA/psilocybin in the United StatesAction: Initiate commercial distribution and market entry strategies for the U.S. market using the allocated 18% of Nasdaq offering proceeds.
- Australian TGA Authorized Prescriber Scheme ExpansionTrigger: Implementation of updated rules broadening therapist eligibility and treatment settingsAction: Scale direct-to-clinic supply chain and increase production runs of 5mg psilocybin and MDMA capsules.
Research as of 20 Jun 2026